In practice, GLP-1 agonists are glucose-dependent
In a randomized, controlled clinical study (Study G), adult patients with type 2 diabetes were randomized to 5 years of treatment with once-daily insulin glargine or twice-daily NPH insulin
Major clinical trials show the most significant changes occur over 6-12+ months when combined with healthy habits
The reality is that if you want to change the world, you have to do it one person at a time
For many patients, this means metformin alone is insufficient for significant or sustained weight reduction
First, and most obviously, GLP-1 may emerge as a promising candidate biomarker for the early detection of gut injury in humans, while also representing a novel therapeutic target for the control of inflammation in the gut